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Aberrant promoter methylation of multiple genes
throughout the clinico-pathologic spectrum 
of B-cell neoplasia
Background and Objectives. Aberrant promoter methylation targets CpG islands caus-
ing gene silencing. We explored aberrant promoter methylation of genes potentially involved
in B-cell malignancies and encoding proteins implicated in DNA repair (O6-methylguanine-
DNA methyltransferase, MGMT), detoxification of environmental xenobiotics (glutathione
S-transferase P1, GSTP1), apoptosis regulation (death associated protein kinase, DAP-k and
caspase 8, CASP8) and cell cycle control (p73).
Design and Methods. Three hundred and seventeen B-cell malignancies were investigated
by methylation-specific polymerase chain reaction (MSP) of MGMT, GSTP1, DAP-k, CASP8
and p73 genes. In selected cases, MSP results were matched to protein expression studies
by immunohistochemistry or Western blotting. 
Results. DAP-k promoter methylation occurred at highest frequency in follicular lym-
phoma (85.0%) and MALT-lymphoma (72.2%). MGMT methylation targeted both precur-
sor B-cell neoplasia (23.8%) and mature B-cell tumors (27.6%). GSTP1 methylation was
commonest in hairy cell leukemia (75.0%), follicular lymphoma (55.5%), Burkitt’s lym-
phoma (52.0%), and MALT lymphoma (50.0%). Methylation of p73 and CASP8 was rare or
absent. DAP-k and MGMT methylation caused absent protein expression.
Interpretation and Conclusions. Methylation of MGMT, DAP-k and GSTP1 represents a
major pathogenetic event in several B-cell malignancies. In follicular lymphoma and MALT
lymphoma, frequent inactivation of the apoptosis extrinsic pathway through DAP-k methy-
lation may reinforce the survival advantage already conferred by deregulation of the intrin-
sic apoptotic pathway. Inactivation of GSTP1 in gastric MALT lymphoma represents an addi-
tional mechanism favoring accumulation of reactive oxygen species and lymphomagene-
sis. Finally, the frequency of GSTP1 aberrant methylation in diffuse large B-cell lymphoma
prompts studies aimed at verifying the prognostic impact of this epigenetic lesion in these
lymphomas. 
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Growing evidence has implicated aber-rant promoter methylation in themolecular pathogenesis of several
human cancers.1-4  Aberrant promoter methy-
lation is an epigenetic DNA modification tar-
geting CpG islands located within the regu-
latory regions of human genes. As a conse-
quence, aberrant methylation of CpG islands
causes repression of gene transcription and
represents a mechanism for tumor suppres-
sor gene inactivation alternative to muta-
tions/deletions of the locus.1-4
To date, the role of aberrant promoter
methylation in B-cell lymphoid malignan-
cies has not been investigated exhaustively,
and extensive studies have been mainly
restricted to the cyclin dependent kinase
inhibitors p15 and p16.5 Although other
genes have been found to be targeted by
aberrant methylation in lymphoid neoplasia,
their analysis has been limited to specific
types of B-cell malignancies or to lymphoid
tumor cell lines.6-9 These observations
prompted our comprehensive analysis aimed
at exploring the prevalence of aberrant pro-
moter methylation in a selected panel of
genes potentially involved in the pathogen-
esis of B-cell malignancies and representa-
tive of genes implicated in DNA repair (O6-
methylguanine-DNA methyltransferase,
MGMT), detoxification of environmental
xenobiotics (glutathione S-transferase P1,
GSTP1), apoptosis regulation (death associ-
ated protein kinase, DAP-k and caspase-8,
CASP8) and cell cycle control (p73). Previous
studies have shown that promoter hyper-
methylation of these genes represents the
major mechanism of gene inactivation,
whereas allelic loss or mutations are virtu-
ally absent.10-11
MGMT is a DNA repair gene that removes
mutagenic and cytotoxic adducts introduced
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into the DNA from environmental and therapeutic alky-
lating agents.12 In particular, MGMT inactivation
increases cell sensitivity to the genotoxic effect of alky-
lating agents both in vitro and in vivo.13,14 The potential
role of MGMT in lymphoma stems from the fact that
MGMT inactivation favors lymphomagenesis in knock-
out mice and represents a favorable prognostic marker
for diffuse large B-cell lymphoma (DLBCL) treated with
regimens containing alkylating agents.8,15
Aberrant promoter methylation of DAP-k has been
suggested to have a potential role in lymphomagene-
sis.7 DAP-k is a pro-apoptotic serine-threonine kinase
involved in the extrinsic pathway of apoptosis initiat-
ed by interferon γ, tumor necrosis factor-α and FAS lig-
and.7,16 In addition, DAP-k also participates in counter-
acting c-MYC-induced transformation by activating the
p53 checkpoint and favoring c-MYC-induced apopto-
sis.17 Consequently, inactivation of DAP-k prevents
apoptosis triggered by death receptors and weakens the
apoptotic response secondary to c-MYC activation. 
GSTP1 is an enzyme implicated in the detoxification
of environmental carcinogens and chemotherapeutic
agents.18 Its loss of expression is a risk factor for the
development of cancer in null mice.19 Although epige-
netic alterations of GSTP1 are recurrent in a wide range
of solid tumors, its methylation pattern in B-cell neo-
plasia is not known.20 Caspase-8 (CASP8) and p73 are
also potential targets of aberrant promoter methyla-
tion in lymphoma.6,21 Similarly to DAP-k, CASP8 is
involved in the extrinsic pathway of programmed cell
death that transduces the apoptotic signal from a death
receptor to the common pathway of apoptosis.21,22 The
p73 gene is a candidate tumor suppressor gene sharing
structural and functional similarities with p53 and is
involved in cell cycle control and apoptosis.23 
In this study we investigated aberrant promoter
methylation of multiple genes in a large panel of B-cell
neoplasms representative of the clinico-pathologic
spectrum of the disease.
Design and Methods
Tumor samples and DNA preparation
This study was based on 317 tumor samples repre-
sentative of  the clinico-pathologic spectrum of B-cell
neoplasia recognized by the WHO classification.24 Tumor
samples were derived from lymph nodes, bone marrow,
peripheral blood or other involved organs obtained dur-
ing routine diagnostic procedures. In all instances, with
the exception of DLBCL transformed from a follicular
phase, the specimens were collected at diagnosis before
specific therapy. Diagnosis was based on morphology
and immunophenotypic analysis of cell surface mark-
ers and was complemented by immunogenotypic analy-
sis of antigen receptor gene rearrangement and chro-
mosomal translocations. In most cases, the fraction of
malignant cells was > 70% and in all cases > 40%.
According to the WHO classification,24 B-cell neoplasia
specimens were classified as precursor B-cell acute lym-
phoblastic leukemia (ALL; n = 21), B-cell chronic lym-
phocytic leukemia (B-CLL; n = 30), lymphoplasmacytic
lymphoma (LPL; n = 9), mantle cell lymphoma (MCL; n
= 19),  follicular lymphoma (FL; n = 21), mucosa-asso-
ciated lymphoid tissue (MALT) lymphoma (n= 11), hairy
cell leukemia (HCL; n = 11), DLBCL (n = 140), mediasti-
nal large B-cell lymphoma (MLBCL; n =10), Burkitt’s
lymphoma (BL; n = 29) and plasma cell myeloma (PCM;
n = 16). The precursor B-cell ALL samples were repre-
sentative of different molecular variants of the disease
and included cases associated with hyperdiploidy (n =
5), BCR/ABL rearrangement (n = 3), MLL rearrangement
(n = 5), TEL/AML-1 rearrangement (n = 3), or not known
genetic lesions (n = 5). MALT lymphomas originated
from the gastrointestinal tract (n = 9) or the thyroid (n
= 2). DLBCL were subdivided into DLBCL arising de novo
without clinical evidence of previous lymphoma (de
novo DLBCL; n = 129) and DLBCL transformed from a
previous follicular lymphoma (transformed DLBCL; n =
11). The study was approved by the institutional review
board and written consent was obtained from the
patients.
Genomic DNA was purified by cell lysis followed by
digestion with proteinase K, salting out extraction, and
precipitation by ethanol.25
Bisulfite treatment
DNA from tumor specimens was subjected to chem-
ical treatment with sodium bisulfite as previously
reported.26 Briefly, 1 µg of DNA was denatured by treat-
ment with NaOH, and modified by sodium bisulfite
treatment for 16 h at 50°C. DNA samples were then
purified using Wizard DNA purification resin (Promega),
desulphonated by incubating in a final concentration of
0.3 M NaOH, precipitated with ethanol, and resus-
pended in water.
Methylation-specific polymerase chain reaction
(MSP)
The modified DNA was used as a template for MSP, a
molecular technique that allows the distinction
between methylated and unmethylated DNA.26 MSP was
performed on 50 ng of bisulfite-treated DNA under the
following conditions: a denaturing step at 95°C for 7
min is followed by 35 cycles at 95°C (30 sec per cycle),
the annealing temperature being specific for each reac-
tion (30 sec per cycle), and 72°C (30 sec per cycle), in a
Hybaid DNA thermal cycler. The PCR mixture contained
10×Gold buffer (Perkin Elmer), 6.7 mM MgCl2, 10 µM of
each primer, 1 mM dNTPs and 0.625 U of Taq Gold
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(Perkin Elmer, 5 U/µL), in a final volume of 25 µL.  
Primers for MGMT were: 5’-TTT GTG TTT TGA TGT TTG
TAG GTT TTT GT-3’ (sense) and 5’-AAC TCC ACA CTC TTC
CAA AAA CAA AAC A-3’ (antisense) for the unmethy-
lated reaction; and 5’-TTT CGA CGT TCG TAG GTT TTC
GC-3’ (sense) and 5’-GCA CTC TTC CGA AAA CGA AAC
G-3’ (antisense) for the methylated reaction.8 The
annealing temperature for both the unmethylated and
the methylated reactions was 59°C. Primers for DAP-k
were: 5’-GGA GGA TAG TTG GAT TGA GTT AAT GTT-3’
(sense) and 5’-CAA ATC CCT CCC AAA CAC CAA-3’ (anti-
sense) for the unmethylated reaction; and 5’-GGA TAG
TCG GAT CGA GTT AAC GTC-3’ (sense) and 5’-CCC TCC
CAA ACG CCG A-3’ (antisense) for the methylated reac-
tion.7 The annealing temperature for both the unmethy-
lated and the methylated reactions was 60°C. Primers
for p73 were: 5’-AGG GGA TGT AGT GAA ATT GGG GTT
T-3’ (sense) and 5’-ATC ACA ACC CCA AAC ATC AAC
ATC CA-3’ (antisense) for the unmethylated reaction;
and 5’- GGA CGT AGC GAA ATC GGG GTT C -3’ (sense)
and 5- ACC CCG AAC ATC GAC GTC CG -3’ (antisense)
for the methylated reaction.6 The annealing temperature
for both the unmethylated and the methylated reac-
tions was 58°C. Primers for CASP8 were: 5’-TAG GGG
ATT TGG AGA TTG TGA-3’ (sense) and 5’-CAT ATA TCT
ACA TTC AAA ACA A-3’ (antisense) for the unmethylat-
ed reaction; and 5’-TAG GGG ATT CGG AGA TTG CGA-
3’ (sense) and 5-CGT ATA TCT ACA TTC GAA ACG A-3’
(antisense) for the methylated reaction.21 The annealing
temperature was 54°C for the unmethylated reaction
and 52°C for the methylated reaction. Primers for GSTP1
were: 5’-GAT GTT TGG GGT GTA GTG GTT GTT -3’ (sense)
and 5’-CCA CCC CAA TAC TAA ATC ACA ACA -3’ (anti-
sense) for the unmethylated reaction; and 5’-TTC GGG
GTG TAG CGG TCG TC-3’ (sense) and 5-GCC CCA ATA
CTA AAT CAC GAC G-3’ (antisense) for the methylated
reaction.20 The annealing temperature was 58°C for the
unmethylated reaction and 52°C for the methylated
reaction.
All MSP analyses were performed with positive and
negative controls for both unmethylated and methy-
lated alleles. Also, control experiments without DNA
were performed for each set of PCR. Ten microliters of
each PCR were directly loaded onto 2.5% agarose gels,
stained with ethidium bromide, and visualized under
UV illumination.
Immunohistochemical staining for MGMT
The correlation between MGMT methylation status
and MGMT protein epression was assessed in a repre-
sentative panel of 28 mature B-cell neoplasms. Paraf-
fin-embedded tissue sections were deparaffinized with
xylene, dehydrated by using a graded series of ethanol
and treated for 30 minutes in TEC (Tris-EDTA-Citrate)
solution (pH 7.8) in a microwave oven at 250 W.
Immunohistochemistry was performed using the ABC
method (ABC-Elite kit, Vector, Burlingame, CA, USA)
with diaminobenzidine as the chromogen. Commer-
cially available  mouse anti-MGMT monoclonal anti-
body (clone MT3.1; Chemicon Intl., Temecula, CA, USA)
at a 1:100 dilution was used.27 This antibody had been
previously demonstrated to be useful for immunohis-
tochemistry and to correlate with MGMT activity.11,28
Nuclear staining was determined by two authors (A.G.
and A.C.) who did not have knowledge of the molecu-
lar analysis of the samples.
Protein preparation and Western blot analysis of
DAP-kinase
Ice cold lysis buffer was used to lyse 107 cells. The
composition of this lysis buffer was as follows: 10 mM
phosphate buffer, pH 7.5, 100 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM EDTA,
1 µg/mL phenylmethyl sulphonyl fluoride (PMSF), and
1× complete protease inhibitor (Boehringer Mannheim).
Subsequently, equal amounts of total protein (400 µg)
from each sample were separated on 7.5% SDS-PAGE
(Bio-Rad, Hercules, CA, USA). The proteins were trans-
ferred onto a nitrocellulose membrane, which was
blocked with 5% BSA/TTBS for 2 hours and then incu-
bated with an anti-DAP-k goat polyclonal antibody
(1:1,000 dilution in 1% BSA/TTBS; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) for 1-2 hours. After wash-
ing, filters were reacted with horseradish peroxidase-
coupled secondary antibody, and revealed with an
enhanced chemiluminescence (ECL) detection system
(Amersham, Arlington Heights, IL, USA) after exposure
to film.
Results
DAP-k, MGMT, GSTP1, p73 and CASP8
methylation in non-neoplastic samples
The sequences of MGMT, DAP-k, GSTP1, p73 and
CASP8 analyzed in our study by MSP are localized in
CpG islands spanning the 5’ non-coding region of the
corresponding genes. The aberrant methylation of these
regions has been reported to be associated with tran-
scriptional silencing.6,7,11,20,21,28
To verify that aberrant methylation of these genes is
limited to neoplastic B-cells, and to exclude the possi-
bility of non-specific reactions, we tested a panel of
non-neoplastic lymphoid tissues represented by normal
peripheral blood leukocytes (n = 5), EBV-immortalized
B lymphocytes (n = 8), and samples of reactive poly-
clonal B-cell hyperplasia (n = 12). None of these non-
neoplastic samples displayed methylation of MGMT,
DAP-k, GSTP1, p73 or CASP8 CpG islands (data not
shown), confirming that aberrant methylation is not
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related to cell culture, viral transformation, cell activa-
tion or proliferation.
Aberrant methylation of MGMT promoter
in B-cell neoplasia
The results of MGMT methylation analysis in B-cell
neoplasia are detailed in Table 1 and representative
examples are shown in Figure 1. Overall, MGMT aber-
rant methylation occurred in both precursor B-cell neo-
plasia (5/21 ALL; 23.8%) and mature B-cell tumors
79/286 (27.6%). MGMT aberrant methylation was het-
erogeneously distributed throughout the entire clini-
co-pathologic spectrum of B-cell neoplasia, and pref-
erentially targeted MLBCL (7/10; 70.0%) and DLBCL
(47/132; 38.0%) among the aggressive lymphomas, and
HCL (4/10; 40.0%), MALT lymphoma (3/11; 27.2%) and
FL (5/20; 25.0%) among the indolent lymphoid malig-
nancies (Table 1).
In order to confirm the biological effect of MGMT
promoter methylation, we performed expression stud-
ies by immunohistochemistry of the MGMT protein in
normal germinal center B cells, which represent the
putative normal counterpart of a large fraction of
mature B-cell lymphoid tumors, and in selected lym-
phoma samples. Immunohistochemistry experiments
showed that i) the MGMT protein is physiologically
expressed by normal germinal center B cells (Figure 2),
which are physiologically unmethylated at the MGMT
promoter; and ii) MGMT promoter methylation corre-
lated with absent MGMT protein expression in lym-
phoma cells. In fact, all (n = 17) lymphoma samples
carrying MGMT aberrant methylation and tested by
immunohistochemistry failed to express the protein in
virtually all tumor cells (Figure 3); conversely, all (n =
11) lymphoma samples carrying unmethylated MGMT
alleles and tested by immunohistohemistry expressed
the MGMT protein (Figure 3).
Aberrant methylation of DAP-k promoter
in B-cell neoplasia
The results of DAP-k promoter methylation in B-cell
neoplasia are detailed in Table 1 and representative
examples are shown in Figure 1. Overall, DAP-k pro-
moter methylation was uncommon in ALL (3/22;
14.2%), while it was frequently observed in mature B-
cell neoplasia (132/281; 46.9%). Among mature B-cell
neoplasms, aberrant methylation of DAP-k did not occur
randomly, but rather clustered with specific clinico-
pathologic categories. In particular, FL and MALT-lym-
phoma showed the highest prevalence of DAP-k aber-
rant methylation, since the aberrant methylation was
detected in 17/20 (85.0%) FL and 8/11 (72.2%) MALT-
lymphomas. DAP-k aberrant methylation was also com-
mon in aggressive NHL, occurring in DLBCL (71/126;
56.3%), MLBCL (6/10; 60.0%) and BL (14/28 50.0%)
(Table 1).
In order to confirm the biological effect of DAP-k
aberrant methylation, we performed expression studies
by Western blot of the DAP-k protein in lymphoma cell
lines. This analysis showed that DAP-k protein was
expressed by lymphoma cell lines unmethylated at the
DAP-k promoter, while DAP-k protein expression was
absent in lymphoma cell lines harboring DAP-k pro-
moter methylation (Figure 4).
Aberrant methylation of GSTP1 promoter
in B-cell neoplasia
GSTP1 promoter hypermethylation was observed in
both ALL (3/11; 27.7%) and mature B-cell neoplasia
(78/207; 37.6%) (Table 1 and Figure 1). Among mature
Table 1. Aberrant methylation of DAP-k, MGMT, GSTP1, p73 and CASP8 in B-cell neoplasia.
Histology DAP-k MGMT GSTP1 p73 CASP8
Precursor B-cell neoplasms
Acute lymphoblastic leukemia 3/22 (14.2 %) 5/21 (23.8 %) 3/11 (27.7%) 3/22 (22.7%) 0/10
Peripheral B-cell neoplasms
B-cell chronic lymphocytic leukemia 8/30 (26.6 %) 3/30 (10.0 %) 1/10 (10.0%) 0/12 0/10
Lymphoplasmacytic lymphoma 0/9 1/9 (11.1 %) 0/7 0/8 0/7
Mantle cell lymphoma 5/19 (26.3 %) 1/18 (5.5 %) 2/8 (25.0%) 0/12 0/9
Follicular lymphoma 17/20 (85.0 %) 5/20 (25.0 %) 10/18 (55.5%) 1/10 (10.0%) 0/9
MALT lymphoma 8/11 (72.2 %) 3/11 (27.2 %) 5/10 (50.0%) 1/11 (9.1%) 0/9
Hairy cell leukemia 3/11 (27.2 %) 4/10 (40.0 %) 6/8 (75.0%) 0/9 0/5
Diffuse large B-cell lymphoma 71/126 (56.3 %) 47/132 (35.6 %) 38/99 (38.3%) 10/113 (8.8%) 0/100
Mediastinal large B-cell lympnoma 6/10 (60.0%) 7/10 (70.0%) 3/10 (30.0%) 0/4 0/10
Burkitt’s lymphoma 14/28 (50.0 %) 5/28 (17.8%) 13/25 (52.0%) 1/9 (9.1%) 0/9
Primary effusion lymphoma 0/1 1/2 0/2 nda nda
Plasma cell myeloma 0/16 2/16 (12.5%) 0/10 0/11 0/10
and: not done.
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B-cell neoplasms, aberrant methylation of GSTP1 was
frequently detected in HCL (6/8; 75.0%) and also
occurred in a fraction of  FL (10/18; 55.5%), BL (13/25;
52.0%), MALT lymphoma (5/10; 50.0%) and DLBCL
(38/99; 38.3%) (Table 1).
p73 promoter hypermethylation in B-cell
neoplasia
Aberrant methylation of p73 occurred in a fraction
of ALL (3/22; 22.7%), while it was uncommon in mature
B-cell neoplasia (13/199; 6.5%) (Table 1). Notably,
among BL cell lines, aberrant methylation of p73
occurred at a remarkably higher frequency (5/11;
45.4%) than among BL primary samples (1/9; 9.1%)
(Table 1).
CASP8 promoter hypermethylation B-cell
neoplasia
None of the B-cell neoplasms investigated in this
study showed promoter methylation of the CASP8 gene
(Table 1).
Longitudinal follow-up of DAP-k, MGMT
and GSTP1 aberrant methylation
In an attempt to clarify the timing of acquisition of
aberrant methylation of DAP-k, MGMT and GSTP1 in
transformed cells, we studied 11 DLBCL transformed
from a previous follicular phase before and after histo-
logic progression (Table 2 and Figure 5). Aberrant
methylation of DAP-k occurred in 7/9 (77.7%) patients
in follicular phase and in 7/9 (77.7%) transformed sam-
Figure 1. Methylation-specific PCR of the genes MGMT (panel A), DAP-k (panel B) and GSTP1 (panel C) in represen-
tative cases of DLBCL. The presence of a visible PCR product in lane M indicates the presence of a methylated allele
(MGMT: 81 bp; DAP-k: 98 bp; GSTP1: 91 bp), while the presence of a product in lane U indicates the presence of
unmethylated alleles (MGMT: 93 bp; DAP-k: 106 bp; GSTP1: 97 bp). In all experiments, the Hela cervical cancer cell
line was used as the positive control for methylated alleles. Peripheral blood (PB) mononuclear cells were used as
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ples. All cases displaying DAP-k methylation in the fol-
licular phase retained this alteration during the pro-
gression to DLBCL. Aberrant methylation of MGMT
occurred in 1/8 (12%) follicular phases and in 2/8 (25%)
transformed samples. In particular, one patient dis-
played aberrant methylation of MGMT in the trans-
formed, but not in the follicular phase, suggesting that
aberrant methylation had been acquired at the time of
histologic progression. Aberrant methylation of GSTP1
occurred in 5/8 (62.5%) patients in follicular phase and
in 4/8 (50.0%) transformed cases. Two patients acquired
and 3 patients lost aberrant GSTP1 methylation at the
time of transformation.
Methylation status of B-cell neoplasia
We performed a comparative analysis of the methy-
lation pattern of B-cell neoplasia. Overall, simultaneous
promoter hypermethylation in ≥ 3/5 genes occurred in
3/10 (30.0%) MALT lymphoma, 2/8 (25.0%) HCL, 11/102
(10.7%) DLBCL, 1/18 (5.5%) FL and 1/24 (4.1%) BL.
Discussion
The aim of this study was a comprehensive investi-
gation of aberrant promoter methylation of multiple
genes throughout the clinico-pathologic spectrum of B-
cell neoplasia. We report that i) aberrant promoter
methylation of MGMT, DAP-k and GSTP1 is involved in
the molecular pathogenesis of B-cell neoplasia; and ii)
MGMT, DAP-k and GSTP1 promoter methylation is not
randomly distributed among B-cell neoplasms, but pref-
erentially targets specific clinico-pathologic categories
of the disease. Overall, these data have multiple impli-
cations for the understanding of the molecular patho-
genesis of B-cell neoplasia.
Figure 2. Panel A: MGMT protein expres-
sion in normal B cells. MGMT protein is
expressed by normal mantle zone (MZ) and
germinal center (GC) B cells. Paraffin-
embedded tissue sections; ABC method,
hematoxylin counterstain. Original magni-
fication ×¥250. Panel B: Methylation-specif-
ic PCR of the MGMT gene in samples of nor-
mal lymph nodes. MGMT promoter is phys-
iologically unmethylated in normal lymph
nodes. MW, molecular weight markers.
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DAP-k aberrant methylation is the commonest epi-
genetic alteration identified to date in FL and MALT
lymphoma, further confirming the role of apopotosis
deregulation in the molecular pathogenesis of these
types of lymphoma. In fact, in lymphoma cells, DAP-k
inactivation results in disruption of the extrinsic path-
way of apoptosis initiated by interferon γ, tumor necro-
sis factor α and FAS ligand.7,16,29 Because resistance to
FAS-induced apoptosis is a common event in B-cell NHL
pathogenesis and appears to occur independently of
FAS gene mutations or FAS protein expression,30 it is
possible that DAP-k methylation may represent a major
determinant of the FAS-resistant phenotype in lym-
phoma. Thus, inactivation of the extrinsic pathway of
apoptosis through DAP-k methylation may reinforce
and possibly co-operate with the survival advantage
conferred to lymphoma cells by BCL-2 deregulation in
FL and NK-κB activation in MALT lymphoma.31 On these
bases, the concomitant disruption of both the intrinsic
and the extrinsic pathways of apoptosis corroborate the
view that FL and MALT lymphomas are diseases of cell
death regulation. DAP-k inactivation may also play a
synergistic role with c-MYC deregulation. In fact, loss
of DAP-k, by downregulating p53, may favor c-MYC-
induced transformation.17 Remarkably, BL, which have c-
MYC deregulation in all cases, also carry DAP-k inacti-
vation in 50% of samples.7
Our results demonstrate that MGMT inactivation
A B
C D
Figure 3. MGMT protein expression in B-cell neoplasia. Panels A-B: Loss of MGMT protein expression in lymphoma
cells (panel A) is demonstrated in a representative case of DLBCL that displays MGMT promoter hypermethylation
(panel B). The occurrence of an unmethylated signal in the methylation-specific PCR of the MGMT gene of this DLB-
CL case (panel B) may be ascribed to the presence of contaminating non-neoplastic cells staining positive for MGMT
expression (panel A). Panel C-D: A case of primary effusion lymphoma (primary sample), unmethylated at the MGMT
promoter (panel D), shows expression of the MGMT protein (panel C). A) Paraffin-embedded tissue section, C) Cell
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through promoter methylation occurs with variable fre-
quencies throughout the entire spectrum of B-cell neo-
plasia. MGMT methylation is selectively restricted to
neoplastic cells and is consistently absent in normal
lymphoid cells, pointing to a pathogenetic role of this
epigenetic lesion. Consistent with the DNA repair func-
tion of MGMT against spontaneous G to A transitions,
MGMT inactivation may cause genetic instability favor-
ing lymphomagenesis through the acquisition of DNA
point mutations.32 The pathogenetic role of MGMT inac-
tivation is further supported by the fact that MGMT
knockout mice develop lymphoma at high frequency.15
Aberrant methylation of GSTP1 occurred frequently in
several types of B-cell malignancies, including 50%
MALT lymphomas. The potential pathogenetic role of
GSTP1 inactivation through promoter methylation is
linked to its important role in scavenging reactive oxy-
gen species and their metabolites and protecting cells
from DNA damage produced by these agents.18 Polymor-
phisms in the GST gene family, to which GSTP1 belongs,
may decrease enzyme activity and have been shown to
be a risk factor for the development of NHL.33-35 In par-
ticular, the risk of gastric MALT lymphoma, which devel-
ops in an inflammatory microenvironment rich in reac-
Figure 4.MSP analysis of
DAP-k promoter hyperme-
thylation (panel A) and
Western Blot analysis of
DAP-k protein and βb−-actin
(as an unrelated protein ref-
erence) expression in vari-
ous B-cell neoplasia cell
lines (panel B). The diffuse
large B-cell lymphoma cell
line Ly1, unmethylated at
the DAP-k gene promoter,
maintains DAP-k protein
expression. In contrast the
Burkitt’s lymphoma cell
lines Raji, Ca46, JD38 and
Walker and the diffuse large
B-cell lymphoma cell lines
Ly8 and Val, which carry
DAP-k promoter hyperme-
thylation, lack DAP-k pro-
tein expression. MW, molec-
ular weight markers.
Table 2.  Longitudinal follow-up of DAP-k, MGMT and GSTP1 aberrant methylation in follicular lymphoma in follicular
phase and after transformation to diffuse large B-cell lymphoma (transformed phase). 
Case Follicular phase Transformed phase
DAP-k MGMT GSTP1 DAP-k MGMT GSTP1
2368 M − − M − −
2700 − M − − M −
2701 M U U M U M
2702 − U − − U −
2703 M U M M U U
2704 M U M M U M
2705 M U U M M U
2706 U U U U U M
2718 U − M U − U
2721 M U M M U M
2723 M − M M − U
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Figure 5. Longitudinal follow-up of DAP-k, MGMT and GSTP1 aberrant methylation by MSP analysis in three repre-
sentative lymphoma cases tested in the follicular phase and after transformation to diffuse large B-cell lymphoma.
Panel A: All cases displaying DAP-k methylation in the follicular phase retain this alteration during progression to dif-
fuse large B-cell lymphoma. Panel B: Case 2705, unmethylated at the MGMT promoter in the follicular phase, acquires
MGMT methylation at the time of histologic progression to diffuse large B-cell lymphoma. Panel C: Case 2701 acquires
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tive oxygen species induced by Helicobacter pylori
infection, is strongly influenced by polymorphisms
affecting the antioxidative capacity mediated by the
GST enzyme family.36 In this respect, the frequent epi-
genetic inactivation of GSTP1 in MALT lymphoma may
provide an alternative mechanism favoring accumula-
tion of reactive oxygen species and lymphomagenesis
in the context of chronic gastric inflammation.
In a longitudinal follow-up, three follicular lymphoma
cases carrying GSTP1 promoter hypermethylation dur-
ing the follicular phase lost GSTP1 methylation in the
transformed phase. Since aberrant promoter hyperme-
thylation is generally an irreversible epigenetic modifi-
cation of DNA,1 it is conceivable that loss of GSTP1
methylation in these cases may have been caused by
the emergence of tumor subclones unmethylated at the
GSTP1 promoter during transformation. Such subclones
may have gained additional genetic lesions that ren-
dered GSTP1 inactivation no longer necessary for neo-
plastic cell survival.
Previous studies have reported a significant frequen-
cy of p73 methylation in DLBCL and in BL.6,10,37,38 In this
report, p73 aberrant methylation was restricted to a
fraction of ALL, while it was virtually absent in all oth-
er primary tumor samples. Discrepancies may be relat-
ed to the lower number of cases previously investigat-
ed or to the predominance of cell line samples in pre-
vious tumor panels. In fact, our results document that
the prevalence of p73 hypermethylation is remarkably
higher in BL cell lines than in BL primary samples, sug-
gesting that p73 methylation may be selected for dur-
ing in vitro establishment and/or growth of lymphoma
cell lines. 
The frequent involvement of MGMT and GSTP1 inac-
tivation in a fraction of B-cell neoplasms may also be
of prognostic relevance. Indeed, MGMT hypermethyla-
tion is a major determinant of alkylator refractoriness
in human tumors and has been shown to predict
improved overall and progression-free survival in DLB-
CL patients treated with conventional cyclophos-
phamide-containing regimens.8 Its prognostic impact
in other B-cell malignancies has not been investigated
to date. GSTP1 is a phase 2 enzyme involved in detox-
ification from chemotherapeutic agents, including dox-
orubicin and alkylating agents.18 Polymorphisms in the
GSTP1 gene may affect the enzyme’s function and have
been associated with lower survival in patients with
breast cancer,39 while high GSTP1 protein expression,
leading to increased detoxification of chemotherapeu-
tic agents, correlates with a worse outcome in DLBCL.40
On these bases, the frequency of GSTP1 aberrant
methylation in DLBCL should prompt studies aimed at
verifying the prognostic impact of this epigenetic lesion
in these lymphomas.
Finally, the simultaneous inactivation of multiple
genes in a lymphoma sample may be of potential sig-
nificance for demethylating therapeutic strategies.4
Because at least a fraction of MALT lymphoma, HCL
and DLBCL display aberrant hypermethylation of ≥3
genes simultaneously, this study prompts future inves-
tigations aimed at analyzing the methylation status of
large number of genes in B-cell neoplasia.
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